In the past week, PROF stock has gone up by 8.75%, with a monthly gain of 4.86% and a quarterly plunge of -13.23%. The volatility ratio for the week is 4.62%, and the volatility levels for the last 30 days are 3.56% for Profound Medical Corp The simple moving average for the past 20 days is 8.74% for PROF’s stock, with a -2.70% simple moving average for the past 200 days.
Is It Worth Investing in Profound Medical Corp (NASDAQ: PROF) Right Now?
Company’s 36-month beta value is 0.86.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PROF is 20.93M, and currently, short sellers hold a 1.60% ratio of that floaft. The average trading volume of PROF on November 05, 2024 was 45.19K shares.
PROF) stock’s latest price update
Profound Medical Corp (NASDAQ: PROF)’s stock price has increased by 11.56 compared to its previous closing price of 7.35. However, the company has seen a 8.75% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-04 that – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that U.S. Centers for Medicare and Medicaid Services (“CMS”) has released its final rule (the “Final Rule”) establishing, for the first time, a Category 1 CPT® code for the Transurethral Ultrasound Ablation (“TULSA”) procedure, effective January 1, 2025. According to the Final Rule, TULSA will have three codes to cover how therapy is delivered depending on if there are one or two physicians involved in the procedure: CPT 51721 TULSA Device Management and CPT 55881 TULSA Treatment, when two physicians are involved in the procedure, and CPT 55882 TULSA Complete Procedure, when performed by a single physician.
Analysts’ Opinion of PROF
Many brokerage firms have already submitted their reports for PROF stocks, with Lake Street repeating the rating for PROF by listing it as a “Buy.” The predicted price for PROF in the upcoming period, according to Lake Street is $16.50 based on the research report published on July 23, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see PROF reach a price target of $12, previously predicting the price at $9. The rating they have provided for PROF stocks is “Buy” according to the report published on July 16th, 2024.
Stifel gave a rating of “Hold” to PROF, setting the target price at $11 in the report published on November 28th of the previous year.
PROF Trading at 4.09% from the 50-Day Moving Average
After a stumble in the market that brought PROF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.85% of loss for the given period.
Volatility was left at 3.56%, however, over the last 30 days, the volatility rate increased by 4.62%, as shares surge +8.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.19% lower at present.
During the last 5 trading sessions, PROF rose by +8.75%, which changed the moving average for the period of 200-days by +2.24% in comparison to the 20-day moving average, which settled at $7.54. In addition, Profound Medical Corp saw -3.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROF starting from Jordan-Cornet Helen, who proposed sale 631 shares at the price of $7.49 back on Sep 23 ’24. After this action, Jordan-Cornet Helen now owns shares of Profound Medical Corp, valued at $4,726 using the latest closing price.
Jordan-Cornet Helen, the Spouse of Profound Medical Corp, proposed sale 564 shares at $7.49 during a trade that took place back on Sep 18 ’24, which means that Jordan-Cornet Helen is holding shares at $4,224 based on the most recent closing price.
Stock Fundamentals for PROF
Current profitability levels for the company are sitting at:
- -3.89 for the present operating margin
- 0.61 for the gross margin
The net margin for Profound Medical Corp stands at -3.51. The total capital return value is set at -0.7. Equity return is now at value -66.00, with -51.65 for asset returns.
Based on Profound Medical Corp (PROF), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -3.68. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -35.2.
Currently, EBITDA for the company is -27.97 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of 21.87. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.61.
Conclusion
In a nutshell, Profound Medical Corp (PROF) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
